A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models
2021 · Acta Pharmaceutica Sinica B · 19 citations
https://doi.org/10.1016/j.apsb.2021.05.019
L
Ling Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
80
Papers
2.5K
Citations
17
h-index
28
i10-index
Ling Li is an academic researcher from Sichuan University. The author has contributed to research in topics: COVID-19 Clinical Research Studies & SARS-CoV-2 and COVID-19 Research & Blood transfusion and management. The author has an h-index of 17, co-authored 68 publications.
ORCID: 0000-0001-6053-6251Papers by this author
worksSystematic Pharmacological Strategies to Explore the Regulatory Mechanism of Ma Xing Shi Gan Decoction on COVID-19
2020 · Digital Chinese Medicine · 13 citations
https://doi.org/10.1016/j.dcmed.2020.06.004
The immune inflammation factors associated with disease severity and poor prognosis in patients with COVID-19: A retrospective cohort study
2023 · Heliyon · 8 citations
https://doi.org/10.1016/j.heliyon.2023.e23583
HNA-3a and HNA-3b antigens among 9 ethnic populations and the Han population in Southwest China
2018 · Journal of Translational Medicine · 4 citations
https://doi.org/10.1186/s12967-018-1447-1
Appropriateness of red blood cell use in China in the last thirteen years: A systematic review
2019 · Heliyon · 3 citations
https://doi.org/10.1016/j.heliyon.2019.e01408
Analysis and Evaluation of China Annual Major Medical Innovation 2022: A Mix‐ Method Approach Study
2023 · Informatics and Health · 1 citations
https://doi.org/10.1016/j.infoh.2023.08.001
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat